SCHEMBL732916

SCHEMBL732916

CC12CC3CC(C)(C1)CC(Br)(C3)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 6/20 0.52
GRIN2A Q12879 6/20 0.52
GRIN2D O15399 5/20 0.52
GRIN3B O60391 5/20 0.52
GRIN2B Q13224 5/20 0.52
GRIN2C Q14957 5/20 0.52
GRIN3A Q8TCU5 5/20 0.52
LMNA P02545 2/20 0.52
HTT P42858 2/20 0.52
SLC22A1 O15245 1/20 0.52
ESR1 P03372 1/20 0.52
ADRB3 P13945 1/20 0.52
ACHE P22303 1/20 0.52
OPRK1 P41145 1/20 0.52
MTOR P42345 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
NFKB1 P19838 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11659282 0.97 GRIN1 (0.54) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
Methyl Alcohol SCHEMBL28176117 0.95 GRIN1 (0.48) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
SCHEMBL3382980 0.95 GRIN1 (0.46) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
SCHEMBL28090077 0.87 GRIN1 (0.42) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
Formic Acid SCHEMBL28177121 0.87 GRIN1 (0.42) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
Acetamide SCHEMBL4785229 0.85 GRIN1 (0.45) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
SCHEMBL812216 0.83 GRIN1 (0.68) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
SCHEMBL26079848 0.83 GRIN1 (0.38) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
Ammonia Solution, Strong SCHEMBL14695768 0.80 GRIN1 (0.65) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B
SCHEMBL11657544 0.80 MEN1 (0.47) GRIN1GRIN2AGRIN2DGRIN3BGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119936252-A Memantine hydrochloride and detection method of related substances thereof 宁夏医科大学 2025-05-06 CN claimed
CN-116947644-B Preparation method of memantine hydrochloride 山东轩鸿生物医药有限公司 2025-01-24 CN claimed
CN-116046926-B Detection method of 1-bromo-3, 5-dimethyl adamantane related substances 合肥久诺医药科技有限公司 2024-11-05 CN claimed
CN-117486929-A Substituted alkyl germanium compound and modularized synthesis method thereof 西安交通大学 2024-02-02 CN claimed
CN-116947644-A Preparation method of memantine hydrochloride 山东轩鸿生物医药有限公司 2023-10-27 CN claimed
CN-116395671-A Preparation method of magnetic carbon quantum dot with high relaxation rate 中国科学院上海微系统与信息技术研究所 2023-07-07 CN claimed
CN-116285974-A Preparation method of carbon-based quantum dot with high quantum yield and light stability 中国科学院上海微系统与信息技术研究所 2023-06-23 CN claimed
CN-111909041-B Preparation method of medicine for treating neurological diseases 山东罗欣药业集团恒欣药业有限公司 2023-06-16 CN claimed
CN-111701600-B Catalyst for preparing 1-bromo-3, 5-dimethyl adamantane and application thereof 沧州那瑞化学科技有限公司 2023-06-06 CN claimed
CN-116046926-A Detection method of 1-bromo-3, 5-dimethyl adamantane related substances 合肥久诺医药科技有限公司 2023-05-02 CN claimed
EP-1836157-A1 PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE Teva Pharmaceutical Fine Chemicals S.R.L. (IT) 2007-09-26 EP claimed
US-20070078283-A1 Method of preparing memantine hydrochloride SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY 2007-04-05 US claimed
WO-2006122238-A1 PROCESS FOR PREPARING MEMANTINE DR. REDDY'S LABORATORIES LTD. (IN) 2006-11-16 WO claimed
US-20060173215-A1 Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride TEVA PHARMACEUTICALS USA, INC. 2006-08-03 US claimed
WO-2006076562-A1 PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) 2006-07-20 WO claimed
EP-1674446-A1 A METHOD OF PREPARING MEMANTINE HYDROCHLORIDE Shanghai Institute of Pharmaceutical Industry (CN) 2006-06-28 EP claimed
CN-1240668-C Method for preparing memantine hydrochloride SHANGHAI INST PHARM INDUSTRY (CN) 2006-02-08 CN claimed
CN-1594277-A Method for preparing memantine hydrochloride SHANGHAI INST PHARM INDUSTRY (CN) 2005-03-16 CN claimed
US-6797745-B1 Hot melt inks containing styrene or terpene polymers XEROX CORPORATION 2004-09-28 US claimed
CN-1400205-A Preparation method of memantine hydrochloride GUANGZHOU INST OF CHEMISTRY (CN) 2003-03-05 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173215-A1 Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride HTR5A, HNMT, HTR1A GRIN1 56/4885GRIN2A 42/4885GRIN2D 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.